Abiomed
This article was originally published in The Gray Sheet
Executive Summary
Approval of a "bridge-to-transplant" indication for the BVS-5000 device has never been sought by the company, as was reported in "The Gray Sheet" (1Aug. 30, p. 11). The device is approved for temporary cardiac support for post-cardiotomy shock, cardiac transplant failure, myocarditis, and right-ventricular assist while the patient is on an implantable left ventricular assist device
You may also be interested in...
Thoratec Should Sever Link Between International And U.S. Websites FDA
Thoratec Laboratories Corp. disputes FDA's assertions in an Aug. 12 warning letter that the company misbranded its VAD device and inappropriately promoted its TLC-II portable VAD driver, which is currently under an approved investigational device exemption.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.